Use of drotrecogin alfa (activated) in a severe acute respiratory syndrome patient with severe sepsis

被引：1
|
作者：
McRitchie, Donna [1 ]
Farooq, Warda [1 ]
Fisher, Harold N. [2 ]
机构：
[1] Univ Toronto, N York Gen Hosp, Toronto, ON, Canada
[2] Eli Lilly Canada Inc, Toronto, ON, Canada
来源：
CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY | 2008年 / 19卷 / 03期
关键词：
D O I：
10.1155/2008/501759
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：258 / 259
页数：2
相关论文
共 50 条
  • [41] Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis
    Weiss, KD
    PEDIATRICS, 2004, 113 (01) : 134 - 134
  • [42] Cost-effectiveness of drotrecogin alfa (activated) (Xigris™) in severe sepsis
    Angus, DC
    Linde-Zwirble, WT
    Clermont, G
    Ball, DE
    Basson, BR
    Ely, EW
    Laterre, PF
    Vincent, JL
    Bernard, GR
    van Hout, B
    CRITICAL CARE MEDICINE, 2002, 30 (02) : 493 - 493
  • [43] Patterns of survival in patients with severe sepsis treated with drotrecogin alfa (activated)
    Williams, MD
    Macias, W
    Nelson, D
    CHEST, 2004, 126 (04) : 723S - 723S
  • [44] Obesity does not alter the pharmacokinetics of drotrecogin alfa (activated) in severe sepsis
    Levy, H
    Small, D
    Heiselman, DE
    Riker, R
    Steingrub, J
    Chen, RQ
    Qualy, RL
    Darstein, C
    Mongan, E
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (02) : 262 - 267
  • [45] Cost effectiveness analysis of drotrecogin alfa (activated) as a treatment for severe sepsis
    Launois, R
    Riou-Franca, L
    Guidet, B
    Aergeter, P
    Meshaka, P
    Pinton, P
    INTENSIVE CARE MEDICINE, 2002, 28 : S161 - S161
  • [46] Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death
    Abraham, E
    Laterre, P
    Garg, R
    Levy, H
    Talwar, D
    Trzaskoma, BL
    Francois, B
    Guy, JS
    Bruckmann, M
    Rea-Neto, A
    Rossaint, R
    Perrotin, D
    Sablotzki, A
    Arkins, N
    Utterback, BG
    Macias, WL
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13): : 1332 - 1341
  • [47] Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death
    Jan O Friedrich
    Neill KJ Adhikari
    Maureen O Meade
    Critical Care, 10
  • [48] Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death
    Friedrich, Jan O.
    Adhikari, Neill K. J.
    Meade, Maureen O.
    CRITICAL CARE, 2006, 10 (06)
  • [49] Introduction: rationale for using drotrecogin alfa (activated) in patients with severe sepsis
    Dhainaut, JF
    AMERICAN JOURNAL OF SURGERY, 2002, 184 (6A): : 5S - 10S
  • [50] Drotrecogin alfa (activated) effects in patients with severe sepsis with or without DIC
    Dhainaut, J
    Yan, B
    INTENSIVE CARE MEDICINE, 2003, 29 : S88 - S88
12345